Just a few weeks after President Donald Trump’s December promise that prescription drug prices would plummet "fast and furious," Patricia Brown checked into a California clinic for an infusion of Merck & Co.'s blockbuster cancer drug, Keytruda.
When the bill arrived, the clinic's charge for a 400 milligram dose dominated the page: $162,567.74.
Brown, an accomplished cook battling lung cancer, owed about $2,000.
But the six-figure charges to Brown and her insurance company show how quickly prices for cutting-edge medical treatments can balloon in the U.S. health care system. Someone has to pay: An employer, taxpayers, or regular people whose insurance premiums go up and up.
The price of Keytruda for Americans starts high and often heads higher. Merck lists Brown’s dose at an already steep $24,000. Then, depending on the insurer, the health care provider and any number of middlemen, prices can rise.
How Merck keeps prices for its blockbuster cancer drug sky high
One of the strictest abortion bans in the country will be on the ballot this November...
Martha Lillard, who contracted polio at age five and spent most of her life dependent on...
One in four Israelis now engages in harmful substance use as the psychological fallout from Israel’s...
New York City’s famed Solomon R Guggenheim Museum was among a number of Manhattan buildings that...
